Pharmaceutical Sales: 70%
Biotechnology Sales: 30%

TOP 3 Markets:

1. South Korea: 40%
2. USA: 30%
3. Europe: 20%

Celltrion Pharm, Inc. generates the majority of its sales from the pharmaceutical industry, with a significant portion also coming from biotechnology. The domestic market of South Korea is the largest single market for the company, followed by the USA and Europe. These markets benefit from Celltrion's focus on innovative biopharmaceutical products and biosimilars, which are in high demand in these regions.

Production Sites: Incheon, South Korea

Celltrion Pharm, Inc. mainly produces its products in Incheon, South Korea. The company has modern production facilities there that are specialized in the manufacturing of biopharmaceutical products. These facilities are designed to meet high quality standards and maximize production capacities.

In addition, Celltrion continuously invests in expanding and modernizing its production facilities to meet the increasing global demands and enhance efficiency.

Focus on Biosimilars: Celltrion Pharm, Inc. strongly emphasizes the development and marketing of biosimilars to drive its growth.

International Expansion: The company plans to expand its presence in international markets, particularly in the USA and Europe.

Research and Development: Celltrion continuously invests in research and development to develop innovative products and expand its product pipeline.

Celltrion Pharm, Inc. pursues a strategy based on strengthening its position in the biosimilar market. By focusing on more cost-effective alternatives to expensive biological drugs, the company aims to benefit from the increasing demand for affordable healthcare solutions.

In addition, Celltrion places great importance on geographical expansion to tap into new markets and reduce dependence on individual regions. This strategy is supported by partnerships and alliances with local companies.

Another key aspect of the growth strategy is the significant investment in research and development. Through this, Celltrion aims to enhance its innovation capabilities and introduce new, competitive products to the market to achieve long-term success.

Main raw materials: Biopharmaceutical active ingredients, chemicals for production

Countries of origin: USA, Germany, China

Celltrion Pharm, Inc. mainly imports biopharmaceutical active ingredients and special chemicals necessary for the production of their biotechnological products. These materials are sourced from various countries, with the USA, Germany, and China being the main suppliers.

The USA and Germany are leaders in providing high-quality pharmaceutical active ingredients and technologies, while China often serves as a source for more cost-effective chemical raw materials. Celltrion utilizes these international supply chains to ensure the quality and efficiency of their production processes.

Market Share in the Biopharma Industry: 8% (2025, estimate)
R&D Expenses as a Percentage of Revenue: 12% (2025)
Patent Portfolio: Over 150 active patents (2025)

Celltrion Pharm, Inc. has a significant competitive advantage in the biopharma industry, supported by several factors. Firstly, the company holds a considerable market share of about 8%, indicating a strong position in the industry.

Secondly, Celltrion invests heavily in research and development, with 12% of revenue allocated to R&D. These investments enable the company to continuously develop innovative products and differentiate itself from competitors.

Furthermore, an extensive patent portfolio of over 150 active patents strengthens Celltrion's market position by ensuring protection and exclusivity for its biopharmaceutical products. Together, these factors give Celltrion a sustainable competitive advantage in a dynamic and competitive market.

Institutional Investor Share: Estimated 45% (2026)

Insider Buys/Sells: No significant changes in the past year (2026)

The institutional investor share in Celltrion Pharm, Inc. is estimated to be around 45%. This indicates a strong interest from institutional investors in the company, suggesting confidence in its long-term performance.

In 2026, there were no significant insider buys or sells, indicating that the management and other insiders do not expect significant changes in their assessment of the company's value. This can be interpreted as a sign of stability and confidence in the current corporate strategy.

Market share of Celltrion Pharm, Inc.: 8% (estimated for 2026)

Top competitors and their market shares:

1. Samsung Biologics: 15%
2. SK Biopharmaceuticals: 12%
3. Hanmi Pharmaceutical: 10%
4. LG Chem Life Sciences: 9%
5. Celltrion Pharm, Inc.: 8%
6. Daewoong Pharmaceutical: 7%
7. Yuhan Corporation: 6%
8. GC Pharma: 5%
9. Korea United Pharm: 4%
10. JW Pharmaceutical: 3%

Moat of Celltrion Pharm, Inc.:

Celltrion Pharm, Inc. has a moderate moat, mainly based on their expertise in biosimilar development. This specialization enables the company to compete in a growing market segment benefiting from increasing demand for cost-effective alternatives to expensive biopharmaceuticals.

Compared to competitors, Samsung Biologics has a stronger moat due to extensive production capacities and strategic partnerships that allow for greater scale efficiency and market penetration. SK Biopharmaceuticals and Hanmi Pharmaceutical also offer strong competitive advantages through innovative research and development programs and a broad product portfolio.

Overall, Celltrion Pharm, Inc. has a solid but not insurmountable moat. Competitors may have the upper hand in some areas, particularly in production efficiency and innovation capabilities.

Revenue Growth: 10% (estimated for 2026 based on the latest available data) Research and Development Expenses: 15% of revenue (2025) Market Share in the Biopharma Industry: 5% (2025)

In recent years, Celltrion Pharm, Inc. has experienced steady revenue growth of around 10%, attributed to a strong product pipeline and successful market launches. The company continues to heavily invest in research and development, accounting for approximately 15% of revenue. These investments could lead to innovative products and a stronger market position in the long term.

Celltrion's market share in the biopharma industry is around 5%, indicating a solid competitive position. Given the increasing demand for biopharmaceuticals and the company's global expansion, this could be a positive signal for future growth.

Overall, Celltrion Pharm, Inc. appears to be a promising investment, especially for investors interested in long-term growth. The strong R&D strategy and market positioning support this assessment.

Dividend Yield: 1.8% (estimated for 2026)
Dividend History: Regular payouts since 2018

Celltrion Pharm, Inc. has pursued a consistent dividend policy in recent years. Since 2018, the company has been regularly paying dividends to its shareholders. The estimated dividend yield for 2026 is around 1.8%, indicating a moderate but stable payout.

The reliability of dividend payments is supported by the company's solid financial performance. Celltrion Pharm has experienced continuous revenue and profit growth in recent years, strengthening its ability to pay dividends. Analysts expect the company to maintain its dividend policy unless significant economic or company-specific challenges arise.